Published in Clin Microbiol Rev on January 01, 1988
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol (1999) 5.58
Toxigenic clostridia. Clin Microbiol Rev (1990) 5.40
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev (1996) 3.46
Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol (1998) 3.34
Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol (2002) 3.30
Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Microbiol Mol Biol Rev (1998) 3.09
Rapid detection of Clostridium difficile in feces by real-time PCR. J Clin Microbiol (2003) 3.08
Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol (2004) 2.82
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol (2000) 2.50
tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol (2006) 2.49
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest (1994) 2.25
Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev (1993) 2.19
Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.07
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut (1997) 1.96
Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile. J Clin Microbiol (2000) 1.91
Survey of incidence of Clostridium difficile infection in Canadian hospitals and diagnostic approaches. J Clin Microbiol (1998) 1.89
Use of cycloserine-cefoxitin-fructose agar and L-proline-aminopeptidase (PRO Discs) in the rapid identification of Clostridium difficile. J Clin Microbiol (1997) 1.85
Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev (2013) 1.85
Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Microbiol (2002) 1.83
Evidence for a modular structure of the homologous repetitive C-terminal carbohydrate-binding sites of Clostridium difficile toxins and Streptococcus mutans glucosyltransferases. J Bacteriol (1992) 1.80
Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol (1993) 1.77
PCR amplification of rRNA intergenic spacer regions as a method for epidemiologic typing of Clostridium difficile. J Clin Microbiol (1995) 1.77
Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol (2006) 1.71
Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun (1994) 1.68
Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol (1991) 1.67
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Multicenter evaluation of a new enzyme immunoassay for detection of Clostridium difficile enterotoxin A. J Clin Microbiol (1992) 1.61
Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun (2000) 1.60
Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens. J Clin Microbiol (1994) 1.56
Specific detection of toxigenic strains of Clostridium difficile in stool specimens. J Clin Microbiol (1993) 1.52
The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile. J Clin Invest (1995) 1.51
Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun (1999) 1.50
Multicenter evaluation of four methods for Clostridium difficile detection: ImmunoCard C. difficile, cytotoxin assay, culture, and latex agglutination. J Clin Microbiol (1996) 1.49
Laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays. J Clin Microbiol (1992) 1.49
Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. Nature (2016) 1.47
Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens. J Clin Microbiol (2002) 1.46
Toxin production by Campylobacter spp. Clin Microbiol Rev (1997) 1.46
Comparison of PCR-based approaches to molecular epidemiologic analysis of Clostridium difficile. J Clin Microbiol (1996) 1.46
Structural organization of the functional domains of Clostridium difficile toxins A and B. Proc Natl Acad Sci U S A (2010) 1.44
Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42
Application of isothermal helicase-dependent amplification with a disposable detection device in a simple sensitive stool test for toxigenic Clostridium difficile. J Mol Diagn (2008) 1.41
Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty? J Mol Diagn (2011) 1.41
Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. J Clin Invest (1997) 1.40
Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun (1988) 1.40
Structure-function analysis of inositol hexakisphosphate-induced autoprocessing in Clostridium difficile toxin A. J Biol Chem (2009) 1.39
Development of a rapid enzyme immunoassay for Clostridium difficile toxin A and its use in the diagnosis of C. difficile-associated disease. J Clin Microbiol (1991) 1.36
Clostridium difficile Toxin B causes epithelial cell necrosis through an autoprocessing-independent mechanism. PLoS Pathog (2012) 1.34
Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun (1997) 1.34
Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity. ChemMedChem (2010) 1.33
Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun (1992) 1.32
Evaluation of four commercially available enzyme immunoassays for laboratory diagnosis of Clostridium difficile-associated diseases. J Clin Microbiol (1993) 1.28
Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR. J Clin Microbiol (2000) 1.28
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother (2001) 1.25
Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun (2011) 1.24
New selective medium for isolating Clostridium difficile from faeces. J Clin Pathol (1992) 1.23
Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile. Infect Immun (2000) 1.23
Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol (2012) 1.22
Antigenic cross-reactivity and functional inhibition by antibodies to Clostridium difficile toxin A, Streptococcus mutans glucan-binding protein, and a synthetic peptide. Infect Immun (1991) 1.21
Evaluation of repeat Clostridium difficile enzyme immunoassay testing. J Clin Microbiol (2008) 1.21
Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. difficile culture and cytotoxin and latex tests. J Clin Microbiol (1992) 1.19
Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother (1996) 1.17
Positive regulation of Clostridium difficile toxins. Infect Immun (1997) 1.17
Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients. Infect Immun (1991) 1.17
Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A. Can J Infect Dis (2004) 1.16
Comparison of two commercially available enzyme immunoassays for detection of Clostridium difficile in stool specimens. J Clin Microbiol (1994) 1.12
Proline-dependent regulation of Clostridium difficile Stickland metabolism. J Bacteriol (2012) 1.09
Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis (2012) 1.09
Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect Immun (1999) 1.09
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine (2009) 1.08
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother (1997) 1.07
Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes. Infect Immun (1997) 1.07
Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun (2007) 1.06
Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun (2006) 1.05
Cloning of a genetic determinant from Clostridium difficile involved in adherence to tissue culture cells and mucus. Infect Immun (1994) 1.03
Identification of Clostridium difficile in stool specimens by culture-enhanced gas-liquid chromatography. J Clin Microbiol (1989) 1.03
Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs (2011) 1.01
Structural basis for substrate recognition in the enzymatic component of ADP-ribosyltransferase toxin CDTa from Clostridium difficile. J Biol Chem (2009) 1.00
Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother (1992) 1.00
Novel one-step method for detection and isolation of active-toxin-producing Clostridium difficile strains directly from stool samples. J Clin Microbiol (2011) 0.98
Genetic relatedness of Clostridium difficile isolates from various origins determined by triple-locus sequence analysis based on toxin regulatory genes tcdC, tcdR, and cdtR. J Clin Microbiol (2008) 0.96
Clostridium difficile-associated diarrhoea: epidemiological data from Western Australia. Epidemiol Infect (1994) 0.96
Expression of Clostridium difficile toxins A and B and their sigma factor TcdD is controlled by temperature. Infect Immun (2003) 0.96
Nutritional aspects of cytotoxin production by Clostridium difficile. Appl Environ Microbiol (1993) 0.96
Evaluation of a commercial latex test for Clostridium difficile for reactivity with C. difficile and cross-reactions with other bacteria. J Clin Microbiol (1988) 0.95
Concurrence of Clostridium difficile toxin A enzyme-linked immunosorbent assay, fecal lactoferrin assay, and clinical criteria with C. difficile cytotoxin titer in two patient cohorts. J Clin Microbiol (1995) 0.92
Purification and characterization of a UDP-glucosyltransferase produced by Legionella pneumophila. Infect Immun (2003) 0.91
Clostridium difficile: a pathogen of the nineties. Eur J Clin Microbiol Infect Dis (1998) 0.91
Comparison of media for screening of diarrheic stools for the recovery of Clostridium difficile. J Clin Microbiol (1989) 0.91
Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. Antimicrob Agents Chemother (1992) 0.91
Effect of Clostridium difficile enterotoxin A on ultrastructure of Chinese hamster ovary cells. Infect Immun (1989) 0.91
Evaluation of three commercial enzyme immunoassay kits for detecting faecal Clostridium difficile toxins. J Clin Pathol (1994) 0.90
Effects of Clostridium difficile toxin B on human monocytes and macrophages: possible relationship with cytoskeletal rearrangement. Infect Immun (1993) 0.90
Adenosine deaminase inhibition prevents Clostridium difficile toxin A-induced enteritis in mice. Infect Immun (2010) 0.90
Clostridium difficile toxin A elicits Ca(2+)-independent cytotoxic effects in cultured normal rat intestinal crypt cells. Infect Immun (1993) 0.89
Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J (2004) 0.89
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65
Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol (1979) 12.54
Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet (1978) 11.99
Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet (1977) 8.77
Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J (1978) 8.47
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Clindamycin-associated colitis. A prospective study. Ann Intern Med (1974) 5.92
Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91
Aetiology of antimicrobial-agent-associated colitis. Lancet (1978) 5.91
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
A new method for the large-scale production of high-titre botulinum formol-toxoid types C and D. J Immunol (1950) 5.19
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J Clin Microbiol (1982) 4.35
Undescribed toxin in pseudomembranous colitis. Br Med J (1977) 4.31
Pseudomembranous colitis: Presence of clostridial toxin. Lancet (1978) 4.30
Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology (1981) 4.04
Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95
Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93
Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr (1980) 3.89
Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis (1981) 3.76
Clostridium defficiel in the urogenital tract of males and females. Lancet (1975) 3.51
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet (1983) 3.24
Pseudo-membranous colitis. Gut (1965) 3.19
Colitis induced by Clostridium difficile. Rev Infect Dis (1980) 3.15
Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis (1984) 3.07
Antibiotic-associated pseudomembranous colitis. Rev Infect Dis (1980) 3.02
Bacteriophage and bacteriocin typing scheme for Clostridium difficile. J Clin Microbiol (1983) 2.97
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65
Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology (1980) 2.60
Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev Infect Dis (1980) 2.59
Clostridial toxin in faeces of healthy infants. Lancet (1978) 2.58
Clindamycin-associated colitis. Review of the clinical spectrum of 47 cases. Am J Dig Dis (1976) 2.52
Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol (1985) 2.46
Clindamycin-induced enterocolitis in hamsters. J Infect Dis (1978) 2.43
Application of whole-cell DNA restriction endonuclease profiles to the epidemiology of Clostridium difficile-induced diarrhea. J Clin Microbiol (1987) 2.34
Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet (1980) 2.26
Biochemical characterization and biologic actions of two toxins (D-1 and D-2) from Clostridium difficile. Rev Infect Dis (1984) 2.26
Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet (1980) 2.24
Epidemiology of Clostridium difficile in infants. J Infect Dis (1982) 2.20
Clostridium difficile in gnotobiotic mice. Infect Immun (1980) 2.17
Fatal enterocolitis in hamsters given lincomycin hydrochloride. Lab Anim Care (1968) 2.17
Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14
Immunochemical fingerprinting of Clostridium difficile strains isolated from an outbreak of antibiotic-associated colitis and diarrhoea. J Med Microbiol (1984) 2.07
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Recovery of Clostridium difficile from children. Scand J Infect Dis (1981) 2.01
Purification and properties of Clostridium difficile cytotoxin B. J Biol Chem (1986) 1.97
Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut (1986) 1.93
Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol (1986) 1.92
Immunological analysis of the EDTA-soluble antigens of Clostridium difficile and related species. J Gen Microbiol (1981) 1.92
In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother (1980) 1.89
Isolation of Clostridium difficile from patients and the environment of hospital wards. J Clin Pathol (1983) 1.89
Clostridium difficile toxin in asymptomatic neonates. J Pediatr (1982) 1.88
Homology between enterotoxin protein and spore structural protein in Clostridium perfringens type A. Eur J Biochem (1973) 1.84
Prevention of clindamycin-induced colitis in hamsters by Clostridium sordellii antitoxin. Gastroenterology (1979) 1.80
Clinical and bacteriological findings in necrotising enterocolitis: a controlled study. J Infect (1980) 1.80
Evaluation of the usefulness of counterimmunoelectrophoresis for diagnosis of Clostridium difficile-associated colitis in clinical specimens. J Clin Microbiol (1983) 1.78
Problems associated with counterimmunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol (1982) 1.75
Purification and characterization of Clostridium sordellii lethal toxin and cross-reactivity with Clostridium difficile cytotoxin. Infect Immun (1987) 1.72
The prevalence of Clostridium difficile and toxin in a nursery population: a comparison between patients with necrotizing enterocolitis and an asymptomatic group. J Pediatr (1982) 1.71
Interaction of cytopathogenic toxin from Clostridium difficile with cells in tissue culture. Scand J Infect Dis Suppl (1980) 1.68
Incidence and origin of Clostridium difficile in neonates. J Clin Microbiol (1984) 1.68
Chemistry of lipid of the posthemyolytic residue or stroma of erythrocytes. XVI. Occurrence of ceramide pentasaccharide in the membrane of erythrocytes and reticulocytes of rabbit. J Biochem (1968) 1.68
Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis. Infect Immun (1981) 1.66
Antibiotic-induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to support the pathogenic role of toxin-producing Clostridia. Am J Vet Res (1978) 1.66
Gas-liquid chromatography as screening test for Clostridium difficile. Lancet (1981) 1.63
Outbreaks of diarrhea associated with Clostridium difficile and its toxin in day-care centers: evidence of person-to-person spread. J Pediatr (1983) 1.63
Growth of Clostridium difficile and production of toxins A and B in complex and defined media. J Med Microbiol (1986) 1.62
Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut (1986) 1.61
Detection of Clostridium difficile toxins A (enterotoxin) and B (cytotoxin) in clinical specimens. Evaluation of a latex agglutination test. Am J Clin Pathol (1986) 1.61
Detection of Clostridium difficile toxin by counterimmunoelectrophoresis: a note of caution. J Clin Microbiol (1981) 1.58
Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun (1987) 1.57
Comparison of bacterial isolation, cytotoxicity assay, and counterimmunoelectrophoresis for the detection of Clostridium difficile and its toxin. J Infect Dis (1983) 1.57
Relative frequency of Clostridium difficile in patients with diarrheal disease. J Clin Microbiol (1981) 1.56
Antibiotic-associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. J Infect Dis (1982) 1.53
Comparison of Minitek Anaerobe II, API An-Ident, and RapID ANA systems for identification of Clostridium difficile. Am J Clin Pathol (1986) 1.53
Commercial latex agglutination test for detection of Clostridium difficile-associated diarrhea. J Clin Microbiol (1987) 1.53
Clostridium difficile toxin A in infants. J Infect Dis (1983) 1.53
Pseudomembranous colitis in Clostridium difficile-monoassociated rats. Infect Immun (1983) 1.51
Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med (1982) 1.51
The use of fluorescein-conjugated Bandeiraea simplicifolia B4-isolectin as a histochemical reagent for the detection of alpha-D-galactopyranosyl groups. Their occurrence in basement membranes. Exp Cell Res (1979) 1.50
An in-vitro model of colonisation resistance to Clostridium difficile infection. J Med Microbiol (1986) 1.50
Modulation of cytotoxin production by Clostridium difficile in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria. Appl Environ Microbiol (1985) 1.47
Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev Biol Stand (1983) 1.45
Acute colitis related to penicillin and penicillin derivatives. Lancet (1978) 1.44
Clostridia colonization and clostridial toxin in neonatal necrotizing enterocolitis. J Pediatr (1981) 1.44
The protective effect of vancomycin on clindamycin-induced colitis in hamsters. Johns Hopkins Med J (1977) 1.42
Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology (1981) 1.42
A selective enrichment broth for the isolation of Clostridium difficile. J Clin Pathol (1984) 1.41
Staphylococcal enterocolitis--treatment with oral vancomycin. Ann Intern Med (1966) 1.41
Simple method for isolation and presumptive identification of Clostridium difficile. Zentralbl Bakteriol Mikrobiol Hyg A (1981) 1.38
Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis. J Clin Pathol (1986) 1.38
Antibiotic-associated pseudomembranous colitis in children. Pediatrics (1981) 1.37
Toxin A of Clostridium difficile: production, purification and effect in mouse intestine. Acta Pathol Microbiol Immunol Scand B (1983) 1.37
Antimicrobial agent-associated colitis and diarrhea: historical background and clinical aspects. Rev Infect Dis (1984) 1.37
Mucosal damage mediated by clostridial toxin in experimental clindamycin-associated colitis. Gut (1980) 1.37
Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis. Am Surg (1981) 1.34
Medium for use in antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1976) 9.38
Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria. Antimicrob Agents Chemother (1973) 9.35
Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol (1977) 8.29
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1979) 5.10
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Development of a micromethod for identification of anaerobic bacteria. Appl Microbiol (1975) 4.58
Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. Appl Environ Microbiol (1977) 4.09
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95
Micromethod for identification of anaerobic bacteria: design and operation of apparatus. Appl Microbiol (1975) 3.80
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res (1990) 2.93
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol (1982) 2.86
Arginine, a growth-limiting factor for Eubacterium lentum. J Bacteriol (1976) 2.67
Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65
Production by Salmonella typhimurium of 2,3-dihydroxybenzoylserine, and its stimulation of growth in human serum. J Infect Dis (1970) 2.62
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Medium-dependent inhibition of Peptostreptococcus anaerobius by sodium polyanetholsulfonate in blood culture media. J Clin Microbiol (1976) 2.46
Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol (1985) 2.46
Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants. Infect Immun (1990) 2.32
Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14
The enterotoxin of Bacteroides fragilis is a metalloprotease. Infect Immun (1995) 2.06
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00
Purification and characterization of an enterotoxin from Bacteroides fragilis. Infect Immun (1992) 1.97
Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol (1986) 1.92
Differential effects of Clostridium difficile toxins on tissue-cultured cells. J Clin Microbiol (1982) 1.87
Resistance of some species of Clostridium to clindamycin. Antimicrob Agents Chemother (1973) 1.81
Effect of clavulanic Acid on anaerobic bacteria resistant to Beta-lactam antibiotics. Antimicrob Agents Chemother (1978) 1.78
In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis. Antimicrob Agents Chemother (1975) 1.78
Problems associated with counterimmunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol (1982) 1.75
Chemotherapy of an experimental Fusobacterium (Sphaerophorus) necrophorum infection in mice. Antimicrob Agents Chemother (1974) 1.71
Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol (1991) 1.67
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Fibrinolytic activity of oral anaerobic bacteria. Arch Oral Biol (1978) 1.65
Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol (1990) 1.65
Use of semisolid agar from initiation of pure Bacteroides fragilis infection in mice. Infect Immun (1976) 1.64
Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. Gastroenterology (1996) 1.63
Inhibition of Bacteroides fragilis on blood agar plates and reversal of inhibition by added hemin. J Clin Microbiol (1976) 1.63
Beta-Lactamase activity in strains of Bacteroides melaninogenicus and Bacteroides oralis. Antimicrob Agents Chemother (1977) 1.62
Laminarinase (beta-glucanase) activity in Bacteroides from the human colon. Appl Environ Microbiol (1977) 1.61
Proteolytic activity of the Bacteroides fragilis enterotoxin causes fluid secretion and intestinal damage in vivo. Infect Immun (1995) 1.59
Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun (1987) 1.57
Purification and characterization of Clostridium perfringens iota toxin: dependence on two nonlinked proteins for biological activity. Infect Immun (1986) 1.57
Requirement of heme for growth of Bacteroides fragilis. Appl Environ Microbiol (1977) 1.53
Clostridium difficile toxin A in infants. J Infect Dis (1983) 1.53
Sialic acid-dependent adhesion of Mycoplasma pneumoniae to purified glycoproteins. J Biol Chem (1989) 1.51
Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal Gal alpha 1-3Gal beta 1-4GlcNAc sequences. Arch Biochem Biophys (1987) 1.51
Vaspar broth-disk procedure for antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1980) 1.50
Molecular basis for the pathological actions of Clostridium perfringens iota toxin. Infect Immun (1987) 1.47
Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of C. difficile. J Med Microbiol (1992) 1.47
The Bacteroides fragilis toxin fragilysin disrupts the paracellular barrier of epithelial cells. Infect Immun (1997) 1.46
Cytochrome spectrum of an obligate anaerobe, Eubacterium lentum. J Bacteriol (1976) 1.45
Bacteriophages of Bacteroides. Rev Infect Dis (1980) 1.44
Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun (1991) 1.44
Clostridium perfringens iota toxin: synergism between two proteins. Toxicon (1986) 1.43
Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42
Cholesterol-reducing bacterium from human feces. Appl Environ Microbiol (1977) 1.40
Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun (1988) 1.40
Influence of pencillinase production by strains of Bacteroides melaninogenicus and Bacteriodes oralis on pencillin therapy of an experimental mixed anaerobic infection in mice. Arch Oral Biol (1976) 1.39
Escherichia coli K99 binds to N-glycolylsialoparagloboside and N-glycolyl-GM3 found in piglet small intestine. Arch Biochem Biophys (1989) 1.36
Cloning and characterization of the gene for the metalloprotease enterotoxin of Bacteroides fragilis. FEMS Microbiol Lett (1997) 1.36
Characterization of cross-reactive proteins detected by Culturette Brand Rapid Latex Test for Clostridium difficile. J Clin Microbiol (1988) 1.34
Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease. Diagn Microbiol Infect Dis (1986) 1.34
Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun (1992) 1.32
Characterization and identification of a porcine small intestine mucus receptor for the K88ab fimbrial adhesin. Infect Immun (1991) 1.28
Cryptococcus neoformans, Candida albicans, and other fungi bind specifically to the glycosphingolipid lactosylceramide (Gal beta 1-4Glc beta 1-1Cer), a possible adhesion receptor for yeasts. Infect Immun (1990) 1.26
Susceptibility of anaerobic bacteria to sulfamethoxazole/trimethoprim and routine susceptibility testing. Antimicrob Agents Chemother (1978) 1.26
Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest (1996) 1.26
Isolation of auxotrophs of Bacteroides fragilis. Can J Microbiol (1978) 1.21
High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C. Proc Natl Acad Sci U S A (1992) 1.20
Antistasin, an inhibitor of coagulation and metastasis, binds to sulfatide (Gal(3-SO4) beta 1-1Cer) and has a sequence homology with other proteins that bind sulfated glycoconjugates. J Biol Chem (1989) 1.20
Positive regulation of Clostridium difficile toxins. Infect Immun (1997) 1.17
Bacteriocin production by strains of Bacteroides isolated from human feces and the role of these strains in the bacterial ecology of the colon. Antimicrob Agents Chemother (1977) 1.16
Mutagenesis of the Clostridium difficile toxin B gene and effect on cytotoxic activity. Microb Pathog (1994) 1.14
TechLab and alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1. J Clin Microbiol (1999) 1.13
The fecapentaenes, potent mutagens from human feces. Chem Res Toxicol (1992) 1.11
Role of Clostridium difficile toxins in disease. Gastroenterology (1987) 1.11
Carbohydrate repression of catalase synthesis in Bacteroides fragilis. J Bacteriol (1977) 1.11
Effect of high-fiber and high-oil diets on the fecal flora of swine. Appl Environ Microbiol (1987) 1.10
Production by Clostridium spiroforme of an iotalike toxin that possesses mono(ADP-ribosyl)transferase activity: identification of a novel class of ADP-ribosyltransferases. Infect Immun (1989) 1.09
Degradation of polysaccharides by intestinal bacterial enzymes. Am J Clin Nutr (1978) 1.07
Transparent plastic incubator for the anaerobic glove box. Appl Environ Microbiol (1977) 1.06
Molecular characterization of the fragilysin pathogenicity islet of enterotoxigenic Bacteroides fragilis. Infect Immun (1998) 1.06
Characterization of enterotoxigenic Bacteroides fragilis by a toxin-specific enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (1994) 1.04
Breakdown of psyllium hydrocolloid by strains of Bacterioides ovatus from the human intestinal tract. Can J Microbiol (1978) 1.04
Comparison of cefoxitin and cephalothin therapy of a mixed Bacteroides fragilis and Fusobacterius necrophorum infection in mice. Antimicrob Agents Chemother (1975) 1.03
Piglet ileal mucus contains protein and glycolipid (galactosylceramide) receptors specific for Escherichia coli K88 fimbriae. Infect Immun (1993) 1.03
Chemotherapy of an experimental Bacteroides fragilis infection in mice. Antimicrob Agents Chemother (1977) 1.01
Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. Eur J Clin Microbiol Infect Dis (2011) 1.01
Two patterns of neutral steroid conversion in the feces of normal North Americans. Cancer Res (1974) 1.00